Loading patent…
AssigneeCollateral Therapeutics
InventorsAndrew Baird, Grai Andreason
Estimating the term…
Novel forms of vascular endothelial growth factor genes and the novel proteins encoded by these genes are disclosed. More particularly, novel forms of human VEGF-A which contain exon 6b and do not contain exon 6a are disclosed. Other novel forms of human VEGF-A contain exon 6b in addition to exon 6a. These novel forms of VEGF-A include VEGF-A138, VEGF-A162, and VEGF-A182. Such novel VEGF proteins may be used in treatment of the cardiovascular system and its diseases through effects on anatomy, conduit function, and permeability, and more particularly in the treatment of cardiovascular disease by stimulating vascular cell proliferation using a growth factor, thereby stimulating endothelial cell growth and vascular permeability. The invention also relates to nucleic acids encoding such novel VEGF proteins, cells, tissues and animals containing such nucleic acids; methods of treatment using such nucleic acids; and methods relating to all of the foregoing.
A purified polypeptide comprising an amino acid sequence coded for by VEGF-A exons 1-5, 6b, and 8, or a derivative thereof.
A purified polypeptide comprising an amino acid sequence coded for by VEGF-A exons 1-5, 6b, 7, and 8, or a derivative thereof.
A purified polypeptide comprising an amino acid sequence coded for by VEGF-A exons 1-5, 6a, 6b, and 8, or a derivative thereof.
A purified and isolated nucleic acid molecule coding for a biologically active fragment of VEGF-A138, or a derivative thereof.
A purified and isolated nucleic acid molecule coding for a biologically active fragment of VEGF-A182, or a derivative thereof.
A purified and isolated nucleic acid molecule coding for a biologically active fragment of VEGF-A162, or a derivative thereof.
A kit for intracoronary injection of a recombinant vector expressing VEGF-A138, VEGF-A162, or VEGF182 comprising:
A method of treating vascular disease in a mammal comprising the step of administering to said mammal VEGF-A138, VEGF-A162, or VEGF-A182 in a therapeutically effective amount to stimulate vascular cell proliferation.
A method for enhancing endothelialization of diseased vessels comprising the step of administering to a mammal a therapeutically effective amount of VEGF-A138, VEGF-A162, or VEGF-A182.
A method of enhancing drug permeation by tumors comprising administering to a patient a nucleic acid molecule coding for VEGF-A138, VEGF-A162, or VEGF182.
A therapeutic composition comprising a pharmaceutically acceptable carrier and VEGF-A138, VEGF-A162, or VEGF-A182 in a therapeutically effective amount to stimulate vascular cell proliferation.
A filtered injectable adenovirus vector preparation, comprising:
A method of treating cardiovascular disease in a mammal comprising the step of transfecting cells of said mammal with a nucleic acid molecule which encodes a polypeptide comprising an amino acid sequence coded for by VEGF-A exons 1-5, 6b and 8.
A method of treating cardiovascular disease in a mammal comprising the step of transfecting cells of said mammal with a nucleic acid molecule which encodes a polypeptide comprising an amino acid sequence coded for by VEGF-A exons 1-5, 6b, 7, and 8.
A method of treating cardiovascular disease in a mammal comprising the step of transfecting cells of said mammal with a nucleic acid molecule which encodes a polypeptide comprising an amino acid sequence coded for by VEGF-A exons 1-5, 6a, 6b, and 8.
A method of treating a patient suffering from an ischemic condition comprising administering a therapeutic amount of a pharmaceutical composition comprising VEGF-A138, VEGF-A162, or VEGF-A182, in a suitable carrier.
A method of increasing vascular permeability comprising administering a therapeutic amount of a pharmaceutical composition comprising VEGF-A138, VEGF-A162, or VEGF-A182 in a suitable carrier.
A method for treating a patient suffering from a wound comprising administering a therapeutic amount of a pharmaceutical composition comprising VEGF-A138, VEGF-A162, or VEGF-A182 in a suitable carrier.
Dependencies are inferred from the claim text.